Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

NewAmsterdam Pharma Q1 EPS $(0.34) Beats $(0.48) Estimate, Sales $2.98M Beat $1.58M Estimate

Author: Benzinga Newsdesk | May 08, 2025 08:13am
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. The company reported quarterly sales of $2.98 million which beat the analyst consensus estimate of $1.58 million by 89.01 percent. This is a 112.56 percent increase over sales of $1.40 million the same period last year.

Posted In: NAMS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist